Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

Conditions

• Head and Neck Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - 120 Years

Healthy Volunteers

Not accepted

Interventions

• erlotinib hydrochloride — DRUG

Study Details

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent and/or metastatic head and neck cancer.

Key Dates

First listed

Jan 25, 2006

Start date

Jul 31, 2005

Status verified

Oct 2016

Primary completion

Oct 31, 2006

Completion

Mar 31, 2007

Study Design

Enrollment

37 participants (estimated)

Allocation

NON_RANDOMIZED

Primary purpose

TREATMENT

Primary Outcome Measure

Relationship between response rate and number of CA repeats in intron 1 of the EGFR

Locations (1)

Find similar trials in Baltimore, MD

Related Studies

• Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
  PHASE2 · Recruiting · National Institute on Deafness and Other Communication Disorders (NIDCD) · Atlanta, Georgia
• Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
  Recruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Washington D.C., District of Columbia
• Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
  Recruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland
• Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
  PHASE2 · Recruiting · University of Maryland, Baltimore · Baltimore, Maryland